Top 11 CRISPR Stocks to Invest In

Page 3 of 10

8. Prime Medicine, Inc. (NASDAQ:PRME)

Number of Hedge Fund Holders: 21

Prime Medicine, Inc. (NASDAQ:PRME) is a clinical-stage biotech company at the forefront of gene editing, specializing in Prime Editing-based therapies. Its proprietary Prime Editing platform offers a groundbreaking approach to gene therapy, enabling precise DNA editing, correction, insertion, and deletion. This technology has the potential to target a broader range of genes and tissues than conventional editing methods. A standout feature is PASSIGE, a proprietary tool that facilitates the efficient insertion of larger genes into DNA, positioning the company uniquely in the competitive gene-editing landscape and paving the way for treatments of complex genetic disorders.

The company’s lead candidate, PM359, is an ex-vivo hematopoietic stem cell-based therapy designed to treat Chronic Granulomatous Disease (CGD). Analysts view this program as relatively low-risk, providing a strong foundation for further clinical development. Prime Medicine, Inc. (NASDAQ:PRME) has also secured a high-profile collaboration with Bristol Myers Squibb, including a $110 million upfront payment, to apply its Prime Editing technology to develop next-generation T-cell therapies for immunology and oncology.

On December 10, JMP Securities initiated coverage of Prime Medicine, Inc. (NASDAQ:PRME) with a Market Outperform rating and a $10 price target, suggesting significant upside from its current price of $3.22. The firm highlighted the company as a leader in Prime Editing, emphasizing the platform’s ability to address genetic targets beyond the reach of earlier gene-editing technologies.

Page 3 of 10